Loading...
•
Dec 31, 2022
Ultragenyx Q4 2022 Earnings Report
Ultragenyx reported Q4 2022 financial results with total revenue of $103.3 million, driven by Crysvita and Dojolvi sales, and provided 2023 revenue guidance.
Key Takeaways
Ultragenyx reported Q4 2022 total revenue of $103.3 million. The company reaffirmed its 2023 financial guidance, expecting total revenue between $425 million and $450 million and net cash used in operations to be less than $400 million.
Total revenue for Q4 2022 was $103.3 million.
Crysvita revenue in Ultragenyx territories was $74.6 million, including $66.9 million in North America collaboration revenue.
Dojolvi revenue was $16.4 million in Q4 2022.
Mepsevii revenue was $4.8 million in Q4 2022.
Revenue by Segment
Forward Guidance
Ultragenyx reaffirms its financial guidance for the full year 2023.
Positive Outlook
- Total revenue in the range of $425 million to $450 million
- Crysvita revenue in the range of $325 million to $340 million, including royalties in Europe and North America.
- Dojolvi revenue in the range of $65 million to $75 million
- Net Cash Used in Operations is expected to be less than $400 million
- Phase 2/3 study dosing patients; Phase 2 enrollment complete, data expected in mid-2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...